| The results of this cost-effectiveness analysis suggest that fulvestrant 500 mg may be a cost-effective option compared with other endocrine monotherapies as a treatment for endocrine therapy-naïve, postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer. |
| Fulvestrant 500 mg is associated with progression-free survival and overall survival gains relative to the comparators. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.